Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | ARHGDIA | P52565 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4973202 | 0.84 | HRH3 (0.45) | — | |
| SCHEMBL4180052 | 0.84 | HRH3 (0.45) | — | |
| SCHEMBL1976244 | 0.80 | ROCK2 (0.44) | ROCK2ARHGDIAROCK1MAPT | |
| SCHEMBL5833037 | 0.80 | MAPT (0.50) | ROCK2ARHGDIAROCK1MAPT | |
| SCHEMBL1976246 | 0.80 | ROCK2 (0.44) | ROCK2ARHGDIAROCK1MAPT | |
| SCHEMBL4966861 | 0.80 | MAPT (0.50) | ROCK2ARHGDIAROCK1MAPT | |
| SCHEMBL5833034 | 0.80 | ROCK2 (0.46) | ROCK2ARHGDIAROCK1MAPT | |
| SCHEMBL4966858 | 0.80 | ROCK2 (0.44) | ROCK2ARHGDIAROCK1MAPT | |
| SCHEMBL5833283 | 0.78 | GBA1 (0.46) | ROCK2ARHGDIAROCK1MAPT | |
| SCHEMBL5833647 | 0.78 | ROCK2 (0.45) | ROCK2ARHGDIAROCK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1189902-B1 | 7-OXO-2-AZABICYCLO[2.2.1]HEPTANES AS SELECTIVE MUSCARINIC RECEPTOR ANTAGONIST | LILLY CO ELI (US) | 2003-08-27 | — | — | EP | claimed |
| US-20090137623-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-05-28 | — | — | US | disclosed |
| EP-1968980-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES, LTD. (IN) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007110782-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-10-04 | — | — | WO | disclosed |
| EP-1189902-B1 | 7-OXO-2-AZABICYCLO[2.2.1]HEPTANES AS SELECTIVE MUSCARINIC RECEPTOR ANTAGONIST | LILLY CO ELI (US) | 2003-08-27 | — | — | EP | disclosed |
| US-6559171-B1 | Muscarinic receptor modulators 7-oxo-2-azabicyclo(2.2.1)heptanes of formula (I) which are useful for the treatment of various diseases and conditions, for example, Alzheimer's disease, glaucoma, psychosis, | ELI LILLY AND COMPANY | 2003-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137623-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM5 | ROCK2 765/4885ARHGDIA 744/4885ROCK1 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.